trial

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

NCTId NCT06947941
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 325 (estimated)
Sponsored by Bristol-Myers
Primary completion 2028-02-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
325 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-03-25
Primary completion
2028-02-21
Eligibility
ALL · 55 Years · 90 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)KarX-EC

Sponsors

Bristol-MyersLead Sponsor

Sites

22 total
Gilbert, United StatesChino, United StatesNaples, United StatesNaples, United StatesCleveland, United StatesIndependence, United StatesMacquarie Park, AustraliaNedlands, AustraliaToronto, CanadaWhitby, CanadaMontreal, CanadaSuita, Japan

Linked catalysts

1
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Ps — primary completion2028-02-21

Facts & assertions

4 sourced
Enrollment
325
Phase
PHASE3
Primary Completion Date
2028-02-21
Status
RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
KarX-EC
drug
lead_sponsor
Bristol-Myers
company
indication
Dementia
indication
Psychosis
indication
Alzheimer Disease
indication